You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 698 A phase 2 study of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) (SABRCURE trial)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
698 A phase 2 study of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) (SABRCURE trial)
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to November 2024

AbstractFullPdf
Nov 2022228014
Dec 20224403
Jan 20235204
Feb 20232405
Mar 20233804
Apr 20232204
May 20239203
Jun 20231803
Jul 20231204
Aug 20231403
Sep 20231200
Oct 20233604
Nov 20232404
Dec 20235204
Jan 20242005
Feb 20243008
Mar 20245205
Apr 20243606
May 20242003
Jun 20244003
Jul 20243603
Aug 20243609
Sep 20244409
Oct 20245008
Nov 202432010
Total10640128